Alliance Pharma Sustainability Profile
Alliance Pharma plc, headquartered in Great Britain, is a prominent player in the pharmaceutical industry, specialising in the development and commercialisation of innovative healthcare products. Founded in 1998, the company has established a strong presence in various operational regions, including Europe and Asia, focusing on prescription medicines and over-the-counter products. With a diverse portfolio that includes unique formulations and niche therapeutic areas, Alliance Pharma is recognised for its commitment to quality and patient care. The company has achieved significant milestones, including strategic acquisitions that have bolstered its market position. Notably, Alliance Pharma has garnered accolades for its effective product range, which addresses unmet medical needs and enhances patient outcomes.
DitchCarbon Score
How does Alliance Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alliance Pharma's score of 53 is higher than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Alliance Pharma's reported carbon emissions
In 2024, Alliance Pharma reported total carbon emissions of approximately 100,990 kg CO2e, with Scope 2 emissions accounting for about 46,000 kg CO2e and Scope 3 emissions contributing significantly at approximately 38,957,000 kg CO2e. The previous year, 2023, saw total emissions of about 101,050 kg CO2e, with Scope 2 emissions at approximately 59,000 kg CO2e and Scope 3 emissions at around 50,125,000 kg CO2e. Notably, Alliance Pharma has not disclosed any Scope 1 emissions for these years. The company has not set specific reduction targets or initiatives as part of the Science Based Targets initiative (SBTi) or other climate pledges. However, they are actively monitoring and reporting their emissions data, which is essential for transparency and accountability in their climate commitments. Alliance Pharma's emissions data is sourced directly from the company, ensuring accuracy and relevance to their operations. The absence of significant reduction targets highlights an area for potential growth in their sustainability strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 7,000 | 00,000 | 0,000 | - | - | - |
| Scope 2 | 107,000 | 00,000 | 00,000 | 00,000 | 00,000 | 00,000 |
| Scope 3 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
How Carbon Intensive is Alliance Pharma's Industry?
How Carbon Intensive is Alliance Pharma's Location?
Alliance Pharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Alliance Pharma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
